Clinical trial · Interventional
Safety and Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Ultra-sound Guided Transversus Abdominis Plan Block in Pediatric Abdominal Cancer Surgery
NCT03979599CI-TRIAL-00065788unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the efficacy of magnesium sulphate as adjuvant to levobupivacaine in transversus abdominis plane (TAP) block in patient undergoing abdominal cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Levobupivacaine | Drug | — | UNRESOLVED |
| magnesium sulphate& levobupivacaine | Drug | — | UNRESOLVED |
| ultra-sound guided transversus abdominis plan block | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- magnesium sulphate& levobupivacaine
- description
- Levobupivacaine add to magnisum sulphate
- interventionNames
- Procedure: ultra-sound guided transversus abdominis plan block
- Drug: magnesium sulphate& levobupivacaine
- type
- PLACEBO_COMPARATOR
- label
- levobupivacaine
- description
- levobupivacaine
- interventionNames
- Procedure: ultra-sound guided transversus abdominis plan block
- Drug: Levobupivacaine
Primary outcomes (1)
- measure
- postoperative pain management
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 7 Years
Show eligibility criteria text
Inclusion Criteria: * patients with (ASA) Ӏ and ӀӀ physical status, aged from 1 to 7 years old and their weight less than 30 Kg of both sex will undergo surgery will be enrolled. Exclusion Criteria: * Children with infection, hemorrhagic disorders, hypersensitivity to the studied drugs, muscular disorders, central and peripheral neuropathy, organ dysfunction, cardiac problems and unconscious or mentally retarded patients will be excluded
References
Publications (0)
Data not yet available
No reference posted for this study.